{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:36:38Z","timestamp":1789900598215,"version":"4.0.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"\n Purpose:<\/jats:title>\n To evaluate the efficacy and safety of valproic acid (VPA) treatment in patients with retinitis pigmentosa (RP).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A total of 48 eyes of 24 patients (13 males, 11 females) with RP prescribed VPA were included. The length of VPA treatment was 6\u201312 months (mean 9.4 months). Parameters evaluated were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution [logMAR]), visual field analyses (VFAs) with Humprey automated perimetry, multifocal electroretinography (ERG) with Roland-RETI scan, and VPA side effects.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Mean age was 34.3 \u00b1 10.3 years (range 18\u201356 years). Fifteen of the patients (30 eyes) had two ERG and VFA tracings, allowing comparison between baseline and follow-up (range 6\u201312 months). Mean BCVA before and after VPA therapy was 0.36 \u00b1 0.38 and 0.36 \u00b1 0.37 logMAR, respectively (\n P<\/jats:italic>\n = 0.32). Quantitative perimetric indices including mean deviation and pattern standard deviation were not significantly changed after VPA therapy (\n P<\/jats:italic>\n > 0.05). P1 amplitudes (in terms of nV\/deg\n 2<\/jats:sup>\n and mV) of ERG waves were significantly decreased in the rings 1, 3, and 4 after VPA therapy (\n P<\/jats:italic>\n < 0.05). Regarding the N1 amplitudes, the only significant decrease was observed in area 1 (\n P<\/jats:italic>\n = 0.03). In addition, N1 latency was significantly increased in area 3 after VPA therapy (\n P<\/jats:italic>\n = 0.04).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n VPA therapy did not have any significant benefit on BCVA and VFA. In addition, it may be associated with decline in some ERG parameters. Therefore, physicians should avoid prescribing VPA for RP until its safety and efficacy are appropriately evaluated.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_978_16","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T08:58:30Z","timestamp":1508230710000},"page":"984-988","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa"],"prefix":"10.4103","volume":"65","author":[{"given":"Y\u00fcksel","family":"Totan","sequence":"first","affiliation":[{"name":"Maya Eye Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"G\u00fcler","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Medipol University Medical School, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131han","family":"Y\u00fcce","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ba\u015fkent University Medical School, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Serdar","family":"Dervi\u015fogullar\u0131","sequence":"additional","affiliation":[{"name":"Medicana Hospital, Eye Clinic, Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251013","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet"},{"key":"R2-20251013","first-page":"3027","article-title":"Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations","volume":"43","author":"Berson","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-20251013","first-page":"704","article-title":"A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa","volume":"137","author":"Hoffman","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R4-20251013","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","article-title":"Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants","volume":"103","author":"Sieving","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"R5-20251013","first-page":"5","article-title":"The history of valproate in clinical neuroscience","volume":"37","author":"Henry","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"R6-20251013","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"R7-20251013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2007.06.053","article-title":"Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity","volume":"149","author":"Chen","year":"2007","journal-title":"Neuroscience"},{"key":"R8-20251013","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.neuroscience.2006.02.065","article-title":"Valproic acid induces caspase 3-mediated apoptosis in microglial cells","volume":"140","author":"Dragunow","year":"2006","journal-title":"Neuroscience"},{"key":"R9-20251013","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbrc.2007.03.135","article-title":"Epigenetic regulation of clusterin\/apolipoprotein J expression in retinal pigment epithelial cells","volume":"357","author":"Suuronen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R10-20251013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.mp.4002099","article-title":"The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons","volume":"14","author":"Yasuda","year":"2009","journal-title":"Mol Psychiatry"},{"key":"R11-20251013","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"R12-20251013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review","volume":"31","author":"Silva","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"R13-20251013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bjo.2009.175356","article-title":"Therapeutic potential of valproic acid for retinitis pigmentosa","volume":"95","author":"Clemson","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R14-20251013","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/bjophthalmol-2012-301950","article-title":"Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa","volume":"96","author":"Sisk","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R15-20251013","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bjophthalmol-2013-303084","article-title":"Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid","volume":"97","author":"Bhalla","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R16-20251013","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1089\/jop.2013.0166","article-title":"Efficacy of oral valproic acid in patients with retinitis pigmentosa","volume":"30","author":"Kumar","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"R17-20251013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-007-9089-2","article-title":"ISCEV guidelines for clinical multifocal electroretinography (2007 edition)","volume":"116","author":"Hood","year":"2008","journal-title":"Doc Ophthalmol"},{"key":"R18-20251013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0301-0082(82)90010-7","article-title":"Mechanism of anticonvulsant action of valproate","volume":"19","author":"Chapman","year":"1982","journal-title":"Prog Neurobiol"},{"key":"R19-20251013","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0006-8993(79)90975-2","article-title":"Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons","volume":"170","author":"Macdonald","year":"1979","journal-title":"Brain Res"},{"key":"R20-20251013","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2006.10.072","article-title":"Conversion of mammalian m\u00fcller glial cells into a neuronal lineage by in vitro aggregate-culture","volume":"351","author":"Kubota","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-20251013","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"R22-20251013","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2147\/OPTH.S109995","article-title":"Efficacy of valproic acid for retinitis pigmentosa patients: A pilot study","volume":"10","author":"Iraha","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R23-20251013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425255.2012.644535","article-title":"Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders","volume":"8","author":"Finsterer","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R24-20251013","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1167\/iovs.07-1360","article-title":"Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography","volume":"49","author":"Nagy","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223307-201765100-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:31:06Z","timestamp":1787758266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223307-201765100-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_978_16","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2016-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}